Centers of Excellence
From the Editor
Relapse, or Resurgence?
One of the biggest misconceptions in all of cancer care and oncology is the notion that a solid tumor ‘recurs’ after local therapy. If, as is often stated, ‘we got it all’ during surgery, then how can a cancer recur? The answer of course is that it was there all along. But that’s only the beginning of the story.
Charles J. Ryan, MD
Charles J. Ryan, MD is Professor of Clinical Medicine and Urology and the Clinical Program Leader for Genitourinary Medical Oncology at the UCSF Helen Diller Family Comprehensive Cancer Center. He received his MD from the University of Wisconsin in Madison and completed his residency in internal medicine at the University of Wisconsin Hospital and Clinics, where he also served as Chief Resident. He completed a fellowship in medical oncology in the Department of Medicine at Memorial Sloan-Kettering Cancer Center and the Joan and Sanford I. Weill Medical College of Cornell University in New York.
ESMO 2017 Prostate Cancer
- ESMO 2017: Patient preference between Cabazitaxel and Docetaxel for first-line chemotherapy in metastatic castration-resistant prostate cancer: results from the CABADOC randomized trial September 11, 2017
- ESMO 2017: Stereotactic Ablative Radiotherapy (SABR) for Oligoprogressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) During Abiraterone Therapy: A Phase I Study September 10, 2017
- ESMO 2017: Randomized phase III trial of ipatasertib vs. placebo, plus abiraterone and prednisone/prednisolone, in men with asymptomatic or mildly symptomatic previously untreated metastatic castrate-resistant prostate cancer (mCRPC) September 10, 2017
- ESMO 2017: Abiraterone acetate + Prednisolone for metastatic Castration-Resistant Prostate Cancer (mCRPC) with early progression or non-response to Androgen Deprivation Therapy September 10, 2017
- ESMO 2017: Benefits of Abiraterone Acetate Plus Prednisone When Added to Androgen Deprivation Therapy in LATITUDE on Patient Reported Outcomes September 9, 2017
- EAU PCa 17: Hormone-naïve metastatic disease: How to treat it?
- EAU PCa 17: Castration resistant prostate cancer: Drug selection and treatment sequencing
- Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
- CARG tool’s ability to predict older prostate cancer patients’ risk of toxicity: Beyond the Abstract
- Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer.